Index Entries

Katherine E. Fleming-Dutra, Amadea Britton, Nong Shang, Gordana Derado, Ruth Link-Gelles, Emma K. Accorsi, Zachary R. Smith, Joseph Miller, Jennifer R. Verani, and Stephanie J. Schrag
May 13, 2022
JAMA (Journal of the American Medical Association)
CDC (Centers for Disease Control and Prevention)

This CDC-funded, case-control analysis tested the vaccine effectiveness (VE) of BNT162b2 against SARS-CoV-2 Omicron. By month 2 after dose 2, estimated effectiveness had dropped to:

  • 28.9% for children 5-11 years of age
  • 16.6% for adolescents 12-15 years of age

In month 3 after dose 2, estimated VE was "no longer significantly different from 0" for adolescents 12-15 years of age. 

"Funding/Support: Funding for the ICATT testing platform is provided by the US Department of Health and Human Services. Funding for this analysis was provided by the Centers for Disease Control and Prevention (CDC).

Role of the Funder/Sponsor: The CDC was involved in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, and approval of the manuscript; and decision to submit the manuscript for publication. The CDC controlled publication decisions." 

document
breakthrough cases,clinical cases,vaccines